BSEAGM/EGMFundraise23 Jun 2026
Parmax Pharma Ltd
Corrigendum to the EGM Notice dated 8th June 2026
Parmax Pharma Ltd has issued a corrigendum to its Extraordinary General Meeting (EGM) notice dated June 8, 2026, which was called for a preferential issue of equity shares and convertible warrants. The corrigendum corrects the proposed status of Ms. Sheetal Hiren Doshi in the warrant allottees table from 'Promoter*' to 'Promoter Group*'. Additionally, a hyperlink for the Practicing Company Secretary’s Certificate in the explanatory statement has been rectified. All other items of the EGM Notice remain unchanged, with the EGM scheduled for July 2, 2026.
BSEInsider Trading / SAST23 Jun 2026
Parmax Pharma Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pradeep Ramniklal Gosalia
A non-promoter shareholder, Pradeep Ramniklal Gosalia, disclosed the disposal of 3,00,000 equity shares of Parmax Pharma Ltd through an off-market transfer on June 18, 2026. This transaction reduced his holding from 8.09% (3,02,714 shares) to 0.07% (2,714 shares). This is a compliance filing under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, reporting a significant reduction in a substantial non-promoter's stake.
BSECompany UpdateM&A23 Jun 2026
Parmax Pharma Ltd
Fedex Securities Pvt Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Public Shareholders of Parmax Pharma Ltd ("Target Company").
Fedex Securities Pvt Ltd, Manager to the Offer, has submitted a Draft Letter of Offer for an open offer to acquire up to 2,346,250 equity shares, representing 26.00% of Parmax Pharma Ltd's expanded voting capital, from its public shareholders. The offer is made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with ten Persons Acting in Concert (PACs), at a price of ₹42.80 per equity share, in compliance with SEBI (SAST) Regulations, 2011.